SS
SLN

Steve Schonfeld’s Silence Therapeutics SLN Stock Holding History

Steve Schonfeld’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.96M Buy
+269,348
New +$1.89M 0.01% 870
2025
Q2 		– Sell
-149,996
Closed -$423K – 2496
2025
Q1 		$423K Buy
149,996
+26,796
+22% +$131K ﹤0.01% 1651
2024
Q4 		$848K Sell
123,200
-42,800
-26% -$552K ﹤0.01% 1186
2024
Q3 		$3.02M Buy
166,000
+90,963
+121% +$1.69M 0.02% 722
2024
Q2 		$1.43M Sell
75,037
-57,963
-44% -$1.23M 0.01% 1052
2024
Q1 		$2.87M Buy
133,000
+83,800
+170% +$1.82M 0.02% 858
2023
Q4 		$855K Buy
49,200
+2,800
+6% +$31.4K 0.01% 1089
2023
Q3 		$456K Sell
46,400
-600
-1% -$4.43K ﹤0.01% 1230
2023
Q2 		$259K Buy
47,000
+5,900
+14% +$35.6K ﹤0.01% 1448
2023
Q1 		$255K Buy
41,100
+11,600
+39% +$137K ﹤0.01% 1446
2022
Q4 		$450K Buy
+29,500
New +$387K ﹤0.01% 1588

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Steve Schonfeld's SLN Position: Q2 2026 in Review

Steve Schonfeld opened a new position in Silence Therapeutics (SLN) in Q2 2026: 269,348 shares worth $2.96M. The stake represents 0.01% of the portfolio and ranks #870 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in SLN as recently as Q1 2025.

Steve Schonfeld first reported a position in SLN in Q4 2022 and has held it in 11 quarters since. The position peaked at $3.02M in Q3 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Steve Schonfeld held 269,348 shares of Silence Therapeutics worth $2.96M as of Q2 2026.
  • Silence Therapeutics was a new Steve Schonfeld position in Q2 2026.
  • Silence Therapeutics made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #870 holding.
  • Steve Schonfeld first reported a position in Silence Therapeutics in Q4 2022 and has held it in 11 quarters since.
  • Steve Schonfeld's Silence Therapeutics position peaked at $3.02M in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.